SCYNEXIS
SCYX | NASDAQ
$2.91
-$0.30 (-9.35%)
At close: Nov 16, 2026, 4:00 PM ET
$2.90
-$0.01 (-0.34%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-9.35%
(1D)No price chart data available for 1D timeframe.
Rating
41.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #475/1021 (Top 47%)
Key Statistics
Market Data
Market Cap $34.46M
1D Range
2.87 3.05
52W Range
2.87 8.88
Valuation (TTM)
PE -2.49
PB 0.58
EV/EBITDA 0.95
Valuation (NTM)
Forward PE 1.21
Forward PEG -0.11
Price Target $33.00
Cash Flow
FCF Yield -35.0%
SBC Adj. FCF Yield -41.9%
SBC Impact -19.9%
Margins
Gross Margin 100.0%
Operating Margin -126.9%
FCF Margin -63.8%
Growth (CAGR)
Revenue 3Y | 5Y -48.2% |
8.5%
Dil EPS 3Y | 5Y 72.0% |
44.7%
FCF 3Y | 5Y 21.8% |
15.2%
Returns
ROA -14.9%
ROE -18.6%
ROIC -38.7%
Financial Health
Net Cash
$47.17M
Current Ratio 7.57
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal...
Sector Healthcare
Industry Medical - Pharmaceuticals
Employees 18
IPO Date May 2, 2014
Website www.scynexis.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.71
Miss -77.50%
YoY:
+47.79% REV
$130.5K
Beat 0.00%
YoY:
-60.93%Next Earnings
Mar 3, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$33.00
Upside
+1034.02%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove SCYX